40
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Comorbidity and multimorbidity in patients with cirrhosis, hospitalised in an internal medicine ward: a monocentric, cross-sectional study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          There are no data regarding the prevalence of comorbidity (ie, additional conditions in reference to an index disease) and multimorbidity (ie, co-occurrence of multiple diseases in which no one holds priority) in patients with liver cirrhosis. We sought to determine the rate and differences between comorbidity and multimorbidity depending on the aetiology of cirrhosis.

          Design

          This is a subanalysis of the San MAtteo Complexity (SMAC) study. We have analysed demographic, clinical characteristics and rate of comorbidity/multimorbidity of patients with liver cirrhosis depending on the aetiology—alcoholic, infectious and non-alcoholic fatty liver disease (NAFLD). A multivariable analysis for factors associated with multimorbidity was fitted.

          Setting

          Single-centre, cross-sectional study conducted in a tertiary referral, academic, internal medicine ward in northern Italy (November 2017–November 2019).

          Participants

          Data from 1433 patients previously enrolled in the SMAC study were assessed; only those with liver cirrhosis were eventually included.

          Results

          Of the 1433 patients, 172 (median age 79 years, IQR 67–84; 83 females) had liver cirrhosis. Patients with cirrhosis displayed higher median Cumulative Illness Rating Scale (CIRS) comorbidity (4, IQR 3–5; p=0.01) and severity (1.85, IQR 16.–2.0; p<0.001) indexes and lower educational level (103, 59.9%; p=0.003). Patients with alcohol cirrhosis were significantly younger (median 65 years, IQR 56–79) than patients with cirrhosis of other aetiologies (p<0.001) and more commonly males (25, 75.8%). Comorbidity was more prevalent in patients with alcohol cirrhosis (13, 39.4%) and multimorbidity was more prevalent in viral (64, 81.0%) and NAFLD (52, 86.7%) cirrhosis (p=0.015). In a multivariable model for factors associated with multimorbidity, a CIRS comorbidity index >3 (OR 2.81, 95% CI 1.14 to 6.93, p=0.024) and admission related to cirrhosis (OR 0.19, 95% CI 0.07 to 0.54, p=0.002) were the only significant associations.

          Conclusions

          Comorbidity is more common in alcohol cirrhosis compared with other aetiologies in a hospital, internal medicine setting.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: not found
          • Article: not found

          EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Liver cirrhosis

              Cirrhosis is widely prevalent worldwide and can be a consequence of different causes, such as obesity, non-alcoholic fatty liver disease, high alcohol consumption, hepatitis B or C infection, autoimmune diseases, cholestatic diseases, and iron or copper overload. Cirrhosis develops after a long period of inflammation that results in replacement of the healthy liver parenchyma with fibrotic tissue and regenerative nodules, leading to portal hypertension. The disease evolves from an asymptomatic phase (compensated cirrhosis) to a symptomatic phase (decompensated cirrhosis), the complications of which often result in hospitalisation, impaired quality of life, and high mortality. Progressive portal hypertension, systemic inflammation, and liver failure drive disease outcomes. The management of liver cirrhosis is centred on the treatment of the causes and complications, and liver transplantation can be required in some cases. In this Seminar, we discuss the disease burden, pathophysiology, and recommendations for the diagnosis and management of cirrhosis and its complications. Future challenges include better screening for early fibrosis or cirrhosis, early identification and reversal of causative factors, and prevention of complications.
                Bookmark

                Author and article information

                Journal
                BMJ Open
                BMJ Open
                bmjopen
                bmjopen
                BMJ Open
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                2044-6055
                2024
                1 May 2024
                : 14
                : 5
                : e077576
                Affiliations
                [1 ] departmentDepartment of Internal Medicine and Medical Therapeutics , Ringgold_19001University of Pavia , Pavia, Italy
                [2 ] departmentDepartment of Internal Medicine , Ringgold_19001Fondazione IRCCS Policlinico San Matteo , Pavia, Italy
                [3 ] departmentService of Clinical Epidemiology & Biometry, Research Department , Ringgold_18631Fondazione IRCCS Policlinico San Matteo , Pavia, Italy
                Author notes
                [Correspondence to ] Professor Gino Roberto Corazza; gr.corazza@ 123456smatteo.pv.it
                Author information
                http://orcid.org/0000-0002-6654-4911
                http://orcid.org/0000-0003-0314-8548
                http://orcid.org/0000-0001-9532-0573
                Article
                bmjopen-2023-077576
                10.1136/bmjopen-2023-077576
                11086508
                38692714
                32fdb156-02eb-4a80-80da-96b8c423723c
                © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:  http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 09 July 2023
                : 25 March 2024
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100007365, Fondazione IRCCS Policlinico San Matteo;
                Award ID: Progetto di Ricerca Corrente 2017
                Categories
                Gastroenterology and Hepatology
                1506
                1695
                Original research
                Custom metadata
                unlocked

                Medicine
                aging,adult gastroenterology,hepatobiliary disease
                Medicine
                aging, adult gastroenterology, hepatobiliary disease

                Comments

                Comment on this article